Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (756)	3/7/1998 9:35:00 AM
From: BD	Read Replies (1) \| Respond to of 887

John, I totally agree, the leak likely wasn't from Depo. there were several entities involved in these discussions. All it takes is a secretary to see a memo or overhear a conversation. Remember everybody and their mother is into the market these days and aware of how valuable information like this can be, they may not be aware of the risks associated with it if they are caught. I feel with conditional approval and drug being ready for market by end of year or early next we could see an intermediary rise to the 10 - 15 range prior to June, with approval easily in the 20's on DC fundimentals alone. Depomorphine then will be the next big product that will be the focus. I really feel good about this technology and company. The technology is tested and documented, it is focused and has a wide range of uses. The company has drug manufacturing ability and best of all cash in the bank that will easily carry it to when DC (if approved) makes it to market. Brian